Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

FGF23 induces left ventricular hypertrophy
Christian Faul, … , Martin G. Keane, Myles Wolf
Christian Faul, … , Martin G. Keane, Myles Wolf
Published October 10, 2011
Citation Information: J Clin Invest. 2011;121(11):4393-4408. https://doi.org/10.1172/JCI46122.
View: Text | PDF
Research Article Nephrology Article has an altmetric score of 30

FGF23 induces left ventricular hypertrophy

  • Text
  • PDF
Abstract

Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor–dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF–receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.

Authors

Christian Faul, Ansel P. Amaral, Behzad Oskouei, Ming-Chang Hu, Alexis Sloan, Tamara Isakova, Orlando M. Gutiérrez, Robier Aguillon-Prada, Joy Lincoln, Joshua M. Hare, Peter Mundel, Azorides Morales, Julia Scialla, Michael Fischer, Elsayed Z. Soliman, Jing Chen, Alan S. Go, Sylvia E. Rosas, Lisa Nessel, Raymond R. Townsend, Harold I. Feldman, Martin St. John Sutton, Akinlolu Ojo, Crystal Gadegbeku, Giovana Seno Di Marco, Stefan Reuter, Dominik Kentrup, Klaus Tiemann, Marcus Brand, Joseph A. Hill, Orson W. Moe, Makoto Kuro-o, John W. Kusek, Martin G. Keane, Myles Wolf

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 23 58 74 87 93 69 85 83 76 66 72 91 84 43 1 1 1006
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2023 (74)

Title and authors Publication Year
HERC1 deficiency causes osteopenia through transcriptional program dysregulation during bone remodeling
Pedrazza L, Martinez-Martinez A, Sánchez-de-Diego C, Valer JA, Pimenta-Lopes C, Sala-Gaston J, Szpak M, Tyler-Smith C, Ventura F, Rosa JL
Cell Death and Disease 2023
Osteocyte Egln1/Phd2 links oxygen sensing and biomineralization via FGF23
Noonan ML, Ni P, Solis E, Marambio YG, Agoro R, Chu X, Wang Y, Gao H, Xuei X, Clinkenbeard EL, Jiang G, Liu S, Stegen S, Carmeliet G, Thompson WR, Liu Y, Wan J, White KE
Bone Research 2023
1,25-dihydroxy vitamin D regulates furin-mediated FGF23 cleavage
Han Xie, Isinsu Bastepe, Wen Zhou, Birol Ay, Zara Ceraj, Ignacio Portales, Sherrie Burnett-Bowie, Harald Juppner, Eugene Rhee, Murat Bastepe, Petra Simic
JCI Insight 2023
Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone—Vascular paradox, a therapeutic target, and a biomarker
Williams MJ, White SC, Joseph Z, Hruska KA
Frontiers in physiology 2023
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
Donovan K, Herrington WG, Paré G, Pigeyre M, Haynes R, Sardell R, Butterworth AS, Folkersen L, Gustafsson S, Wang Q, Baigent C, Mälarstig A, Holmes MV, Staplin N
Clinical journal of the American Society of Nephrology : CJASN 2023
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N
Frontiers in Endocrinology 2023
FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia
Figurek A, Rroji M, Spasovski G
Cells 2023
Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice
Chen G, An N, Shen J, Chen H, Chen Y, Sun J, Hu Z, Qiu J, Jin C, He S, Mei L, Sui Y, Li W, Chen P, Guan X, Chu M, Wang Y, Jin L, Kim K, Li X, Cong W, Wang X
Nature Communications 2023
Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension.
Widmann L, Keranov S, Jafari L, Liebetrau C, Keller T, Troidl C, Kriechbaum S, Voss S, Arsalan M, Richter MJ, Tello K, Gall H, Ghofrani HA, Guth S, Seeger W, Hamm CW, Dörr O, Nef H
Clinical research in cardiology : official journal of the German Cardiac Society 2023
Fibroblast growth factor 23 in children with or without heart failure: a prospective study.
Elzayat RS, Bahbah WA, Elzaiat RS, Elgazzar BA
BMJ paediatrics open 2023
Mineral bone disorder in children with chronic kidney disease: Data from the KNOW-Ped CKD (Korean cohort study for outcome in patients with pediatric chronic kidney disease) study
Jung J, Lee KH, Park E, Park YS, Kang HG, Ahn YH, Ha IS, Kim SH, Cho H, Han KH, Cho MH, Choi HJ, Lee JH, Shin JI
Frontiers in Pediatrics 2023
Indoxyl sulfate induces left ventricular hypertrophy via the AhR-FGF23-FGFR4 signaling pathway
Kishimoto H, Nakano T, Torisu K, Tokumoto M, Uchida Y, Yamada S, Taniguchi M, Kitazono T
Frontiers in Cardiovascular Medicine 2023
Direct and indirect effects of fibroblast growth factor 23 on the heart
Nakano T, Kishimoto H, Tokumoto M
Frontiers in Endocrinology 2023
Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects.
Komaba H
Clinical and Experimental Nephrology 2023
Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease
Dozio E, Caldiroli L, Molinari P, Castellano G, Delfrate NW, Romanelli MM, Vettoretti S
Antioxidants 2023
Zebrafish as a Model of Cardiac Pathology and Toxicity: Spotlight on Uremic Toxins.
Coppola A, Lombari P, Mazzella E, Capolongo G, Simeoni M, Perna AF, Ingrosso D, Borriello M
International journal of molecular sciences 2023
A potential link between fibroblast growth factor-23 and the progression of AKI to CKD
Lu Y, Xu S, Tang R, Han C, Zheng C
BMC Nephrology 2023
Crosstalk between bone and muscle in chronic kidney disease.
Wong L, McMahon LP
Frontiers in Endocrinology 2023
Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23
Pons-Belda OD, Alonso-Álvarez MA, González-Rodríguez JD, Mantecón-Fernández L, Santos-Rodríguez F
International journal of molecular sciences 2023
Vitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines
Bover J, Massó E, Gifre L, Alfieri C, Soler-Majoral J, Fusaro M, Calabia J, Rodríguez-Pena R, Rodríguez-Chitiva N, López-Báez V, Sánchez-Baya M, da Silva I, Aguilar A, Bustos MC, Rodrigues N, Chávez-Iñiguez JS, Romero-González G, Valdivielso JM, Molina P, Górriz JL
Nutrients 2023
The role of Klotho and FGF23 in cardiovascular outcomes of diabetic patients with chronic limb threatening ischemia: a prospective study.
Biscetti F, Rando MM, Cecchini AL, Nicolazzi MA, Rossini E, Angelini F, Iezzi R, Eraso LH, Dimuzio PJ, Pitocco D, Gasbarrini A, Massetti M, Flex A
Scientific Reports 2023
Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery
Hofer F, Hammer A, Pailer U, Koller L, Kazem N, Steinacher E, Steinlechner B, Andreas M, Laufer G, Wojta J, Zelniker TA, Hengstenberg C, Niessner A, Sulzgruber P
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2023
Correlation of Serum FGF23 and Chronic Kidney Disease-Mineral and Bone Abnormality Markers With Cardiac Structure Changes in Maintenance Hemodialysis Patients
Zeng D, Zha A, Lei Y, Yu Z, Cao R, Li L, Song Z, Li W, Li Y, Liu H, Huang S, Dong X, Krämer B, Hocher B, Yin L, Yun C, Morgera S, Guan B, Meng Y, Liu F, Hu B, Luan S
Evidence-based complementary and alternative medicine : eCAM 2023
Different Efficacy of Burosumab on Physical Performance and Serum Phosphate in Adult Patients with X-Linked Hyphophosphatemic Rickets during the First Six-Month of Treatment.
Arcidiacono T, Foligno NE, Brioni E, Bologna A, Weber G, Mora S, Pitea M, Vitale C, Vezzoli G
Journal of Clinical Medicine 2023
The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis
Coimbra S, Catarino C, Sameiro Faria M, Nunes JP, Rocha S, Valente MJ, Rocha-Pereira P, Bronze-da-Rocha E, Bettencourt N, Beco A, Marques SH, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Belo L, Santos-Silva A
Biomedicines 2023
Regulation of the Osteocyte Secretome with Aging and Disease.
Kitase Y, Prideaux M
Calcified Tissue International 2023
Oncostatin M is a regulator of fibroblast growth factor 23 (FGF23) in UMR106 osteoblast-like cells
Münz S, Feger M, Föller M
Scientific Reports 2023
Fibroblast growth factor 23, klotho and heparin
Thomas SM, Li Q, Faul C
Current Opinion in Nephrology and Hypertension 2023
Transcriptomic analysis identifies novel candidates in cardiorenal pathology mediated by chronic peritoneal dialysis
Nasci VL, Liu P, Marks AM, Williams AC, Kriegel AJ
Scientific Reports 2023
Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population
Kurpas A, Supel K, Wieczorkiewicz P, Bodalska Duleba J, Zielinska M
Biomedicines 2023
The Importance of the Nephrologist in the Treatment of the Diuretic-Resistant Heart Failure
Pethő ÁG, Tapolyai M, Browne M, Fülöp T, Orosz P, Szabó RP
Life Sciences 2023
Mendelian randomization and the association of fibroblast growth factor-23 with heart failure with preserved ejection fraction.
Akwo EA, Robinson-Cohen C
Current Opinion in Nephrology and Hypertension 2023
Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity.
Clinkenbeard E
Calcified Tissue International 2023
FGF23 and klotho at the intersection of kidney and cardiovascular disease.
Edmonston D, Grabner A, Wolf M
Nature reviews. Cardiology 2023
Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation
Courbon G, Thomas JJ, Martinez-Calle M, Wang X, Spindler J, Von Drasek J, Hunt-Tobey B, Mehta R, Isakova T, Chang W, Creemers JW, Ji P, Martin A, David V
Blood 2023
Fibroblast growth factor-23 and cardiovascular disease among prevalent hemodialysis patients focusing on residual kidney function
Kee YK, Jeon HJ, Oh J, Cho A, Lee YK, Yoon JW, Kim H, Yoo TH, Shin DH
Frontiers in Endocrinology 2023
Cardiac Mechanics and Kidney Function Decline in the Cardiovascular Health Study
Mehta R, Buzkova P, Patel H, Cheng J, Kizer JR, Gottdiener JS, Psaty B, Khan SS, Ix JH, Isakova T, Shlipak MG, Bansal N, Shah SJ
2023
Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
Yamada S, Nakano T
Journal of Atherosclerosis and Thrombosis 2023
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Vergaro G, Del Franco A, Aimo A, Gentile F, Castiglione V, Saponaro F, Masotti S, Prontera C, Fusari N, Emdin M, Passino C
BMC Cardiovascular Disorders 2023
Bone marrow sinusoidal endothelial cells are a site of Fgf23 upregulation in a mouse model of iron deficiency anemia
Li X, Lozovatsky L, Tommasini SM, Fretz J, Finberg KE
Blood Advances 2023
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Wiecek A
Cardiovascular Research 2023
Removal of calciprotein particles from the blood using an adsorption column improves prognosis of hemodialysis miniature pigs
Miura M, Miura Y, Iwazu Y, Mukai H, Sugiura T, Suzuki Y, Kato M, Kano M, Nagata D, Shiizaki K, Kurosu H, Kuro-o M
Scientific Reports 2023
Klotho/FGF23 Axis Regulates Cardiomyocyte Apoptosis and Cytokine Release through ERK/MAPK Pathway.
Jia Z, Liu Q, Xie Y, Wei J, Sun X, Meng F, Zhao B, Yu Z, Zhao L, Xing Z
Cardiovascular Toxicology 2023
Assessment and management of heart failure in patients with chronic kidney disease.
Guaricci AI, Sturdà F, Russo R, Basile P, Baggiano A, Mushtaq S, Fusini L, Fazzari F, Bertandino F, Monitillo F, Carella MC, Simonini M, Pontone G, Ciccone MM, Grandaliano G, Vezzoli G, Pesce F
Heart Failure Reviews 2023
Bibliometric study and review of Klotho research: global characteristics and trends from 2000 to 2023.
Zhang FF, Xu YQ, Xiong JH, Hu JX, Zhu GS, Cheng SM
International Urology and Nephrology 2023
The effect of intradialytic exercise on calcium, phosphorus and parathyroid hormone: a randomized controlled trial.
Tabibi MA, Wilund KR, Salimian N, Nikbakht S, Soleymany M, Roshanaeian Z, Nazemi F, Ahmadi S
BMC Nephrology 2023
FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
Benes J, Kroupova K, Kotrc M, Petrak J, Jarolim P, Novosadova V, Kautzner J, Melenovsky V
Scientific Reports 2023
MCP1 Inverts the Correlation between FGF23 and Omega 6/3 Ratio: Is It Also True in Renal Transplantation?
Mattinzoli D, Turolo S, Ikehata M, Vettoretti S, Montini G, Agostoni C, Conti C, Benedetti M, Messa P, Alfieri CM, Castellano G
Journal of Clinical Medicine 2023
Knowledge landscapes and emerging trends of cardiorenal syndrome type 4: a bibliometrics and visual analysis from 2004 to 2022.
Li H, Liu T, Yang L, Ma F, Wang Y, Zhan Y, Mao H
International Urology and Nephrology 2023
Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort
Sunderraj A, Wong M, Gutiérrez OM, Wolf M, Akhabue E, Carnethon MR, Yancy CW, Isakova T
2023
Physiopathology of Phosphate Disorders
Portales-Castillo I, Rieg T, Khalid SB, Nigwekar SU, Neyra JA
2023
Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study
Leidner AS, Cai X, Zelnick LR, Lee J, Bansal N, Pasch A, Kansal M, Chen J, Anderson AH, Sondheimer JH, Lash JP, Townsend RR, Go AS, Feldman HI, Shah SJ, Wolf M, Isakova T, Mehta RC
2023
Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology
Junho CV, Frisch J, Soppert J, Wollenhaupt J, Noels H
Clinical Kidney Journal 2023
Associations between anemia and FGF23 in the CKiD study.
Thomas E, Klomhaus AM, Laster ML, Furth SL, Warady BA, Salusky IB, Hanudel MR
Pediatric nephrology (Berlin, Germany) 2023
High pretransplant FGF23 level is associated with persistent vitamin D insufficiency and poor graft survival in kidney transplant patients
Ryu JH, Jeon HJ, Han R, Jung HY, Kim MG, Huh KH, Park JB, Kang KP, Han S, Yang J
Scientific Reports 2023
Fibroblast growth factor 23 but not copeptin is independently associated with kidney failure and mortality in patients with chronic kidney disease
Michon-Colin A, Metzger M, Bankir L, Gauci C, Brunel M, Baron S, Prot-Bertoye C, Stengel B, Thervet E, Haymann JP, Boffa JJ, Vrtovsnik F, Flamant M, Houillier P, Prie D, Courbebaisse M
Clinical Kidney Journal 2023
Novel mechanism of the COVID-19 associated coagulopathy (CAC) and vascular thromboembolism.
Singh M, Pushpakumar S, Zheng Y, Smolenkova I, Akinterinwa OE, Luulay B, Tyagi SC
2023
Echocardiographic manifestations in end-stage renal disease.
Ito T, Akamatsu K
Heart Failure Reviews 2023
Cardioprotective and Antifibrotic Effects of Low-Dose Renin-Angiotensin-Aldosterone System Inhibitors in Type 1 Diabetic Rat Model.
Balogh DB, Molnar A, Degi A, Toth A, Lenart L, Saeed A, Barczi A, Szabo AJ, Wagner LJ, Reusz G, Fekete A
International journal of molecular sciences 2023
The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment
Yun L, YuMei Z, BN V, Tang Q, Feng C
Cureus 2023
NT-proBNP Mediates the Association Between FGF23 and All-Cause Mortality in Individuals With Type 2 Diabetes.
van der Vaart A, Bakker SJL, Laverman GD, van Dijk PR, de Borst MH
Journal of the American Heart Association 2023
'Phos'tering a Clear Message: The Evolution of Dietary Phosphorus Management in Chronic Kidney Disease.
Biruete A, Hill Gallant KM, Lloyd L, Meade A, Moe SM, St-Jules DE, Kistler BM
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2023
The Dietary Fiber Inulin Slows Progression of Chronic Kidney Disease–Mineral Bone Disorder (CKD‐MBD) in a Rat Model of CKD
Biruete A, Chen NX, Metzger CE, Srinivasan S, O'Neill K, Fallen PB, Fonseca A, Wilson HE, de Loor H, Evenepoel P, Swanson KS, Allen MR, Moe SM
JBMR Plus 2023
Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease
Watanabe K, Fujii H, Okamoto K, Kono K, Goto S, Nishi S
Frontiers in Endocrinology 2023
Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease.
Ogata H, Sugawara H, Yamamoto M, Ito H
Journal of Atherosclerosis and Thrombosis 2023
Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease
Fuchs MA, Burke EJ, Latic N, Murray S, Li H, Sparks M, Abraham D, Zhang H, Rosenberg P, Hänzelmann S, Hausmann F, Huber T, Erben R, Fisher-Wellman K, Bursac N, Wolf M, Grabner A
Research square 2023
Beta Blockade Prevents Cardiac Morphological and Molecular Remodelling in Experimental Uremia.
Chinnappa S, Maqbool A, Viswambharan H, Mooney A, Denby L, Drinkhill M
International journal of molecular sciences 2023
Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?
Cepoi MR, Duca ST, Chetran A, Costache AD, Spiridon MR, Afrăsânie I, Leancă SA, Dmour BA, Matei IT, Miftode RS, Miftode L, Prepeliuc CS, Haba MȘ, Bădescu MC, Costache II
Life Sciences 2023
Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome
Kallmeyer A, Pello A, Cánovas E, Aceña Á, González\u2010Casaus ML, Tarín N, Cristóbal C, Gutiérrez\u2010Landaluce C, Huelmos A, Rodríguez\u2010Valer A, González\u2010Lorenzo Ó, Alonso J, López\u2010Bescós L, Egido J, Mahillo I, Lorenzo Ó, Tuñón J
ESC Heart Failure 2023
The basics of phosphate metabolism
Wagner CA
Nephrology Dialysis Transplantation 2023
Iron Status and Cause-Specific Mortality After Kidney Transplantation
Vinke JS, Kremer D, Knobbe TJ, Grote Beverborg N, Berger SP, Bakker SJ, de Borst MH, Eisenga MF
2023
Impact of Electrocardiographic Parameters on Sudden Death in Patients Receiving Maintenance Hemodialysis: Ten-Year Outcomes of the Q-Cohort Study
Hiyamuta H, Yamada S, Nakano T, Taniguchi M, Masutani K, Tsuruya K, Kitazono T
Journal of Atherosclerosis and Thrombosis 2023
FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis
Hidaka N, Inoue K, Kato H, Hoshino Y, Koga M, Kinoshita Y, Takashi Y, Makita N, Fukumoto S, Nangaku M, Ito N
2023
Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
Zhang Z, Wang Y
2023

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 8 X users
Referenced in 17 patents
Referenced in 6 Wikipedia pages
Highlighted by 1 platforms
Referenced in 1 clinical guideline sources
654 readers on Mendeley
1 readers on CiteULike
See more details